Another formulation, ILP (34A-PEG-ILP), conjugated to antibodies at the distal PEG end, demonstrated superior targeting efficiency to lung endothelial cells and tumour tissue compared with conventional liposomes (136). Here, XIAP is linked to neoplasm.